Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cytokinetics (CYTK – Research Report), Medtronic (MDT – Research Report) and Option Care Health (OPCH – Research Report).
Cytokinetics (CYTK)
Bank of America Securities analyst Jason Zemansky maintained a Hold rating on Cytokinetics yesterday and set a price target of $41.00. The company’s shares closed last Thursday at $32.81.
According to TipRanks.com, Zemansky is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $62.36 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Medtronic (MDT)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Medtronic yesterday and set a price target of $102.00. The company’s shares closed last Thursday at $72.35, close to its 52-week low of $70.95.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $89.80 average price target, representing a 23.6% upside. In a report issued on October 17, Mizuho Securities also maintained a Buy rating on the stock with a $90.00 price target.
Option Care Health (OPCH)
In a report released today, Joanna Gajuk from Bank of America Securities reiterated a Buy rating on Option Care Health, with a price target of $43.00. The company’s shares closed last Thursday at $32.33.
According to TipRanks.com, Gajuk is a 3-star analyst with an average return of
Option Care Health has an analyst consensus of Strong Buy, with a price target consensus of $42.00, which is a 30.6% upside from current levels. In a report issued on October 10, Barrington also maintained a Buy rating on the stock with a $41.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
- Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
- Cytokinetics price target raised to $65 from $59 at Cantor Fitzgerald
- Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
- Cytokinetics presents baseline characteristics from Sequoia-HCM
- Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
